‘Too many patients’ struggled to pay

A glut of patients who were prescribed Repatha, Amgen’s treatment for high cholesterol, but couldn’t pay for the pricey treatment, were top of mind in the company’s decision to cut the drug’s cost by 60 percent, Amgen Chairman and CEO Bob Bradway said Monday. In October, Amgen cut the price for a biweekly dose of […]

Continue Reading